Arvinas (ARVN) Accounts Payables (2017 - 2026)
Arvinas (ARVN) posted quarterly Accounts Payables of $62.3 million for Q1 2026, down 12.38% year-over-year from $71.1 million in Q1 2025, and down 10.36% quarter-over-quarter from $69.5 million in Q4 2025.
Arvinas (ARVN) Accounts Payables (2017 - 2026) Analysis & Trends
Arvinas' Accounts Payables history runs 10 years deep, the most recent figure standing at $62.3 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 12.38% year-over-year to $62.3 million; the TTM figure through Mar 2026 stood at $62.3 million (down 12.38% YoY), while the FY2025 annual figure was $69.5 million, down 3.2% from the prior year.
- Accounts Payables for Q1 2026 stood at $62.3 million, down from $69.5 million in the prior quarter.
- The five-year high for Accounts Payables was $92.2 million in Q4 2023, with the low at $8.6 million in Q1 2022.
- The 5-year median for Accounts Payables is $71.1 million (2025), against an average of $65.5 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 963.87% in 2022, then slumped 32.01% in 2025.
- Arvinas' Accounts Payables stood at $74.7 million in 2022, then grew by 23.43% to $92.2 million in 2023, then retreated by 22.13% to $71.8 million in 2024, then declined by 3.2% to $69.5 million in 2025, then declined by 10.36% to $62.3 million in 2026.
- Business Quant data shows ARVN's Accounts Payables at $62.3 million in Q1 2026, $69.5 million in Q4 2025, and $55.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 52.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.20 Mn |
| Mar 31, 2026 | 62.30 Mn |
| Dec 31, 2025 | 69.50 Mn |
| Sep 30, 2025 | 55.50 Mn |
| Jun 30, 2025 | 53.10 Mn |
| Mar 31, 2025 | 71.10 Mn |
| Dec 31, 2024 | 71.80 Mn |
| Sep 30, 2024 | 75.90 Mn |
| Jun 30, 2024 | 78.10 Mn |
| Mar 31, 2024 | 76.40 Mn |
| Dec 31, 2023 | 92.20 Mn |
| Sep 30, 2023 | 91.00 Mn |
| Jun 30, 2023 | 74.80 Mn |
| Mar 31, 2023 | 66.00 Mn |
| Dec 31, 2022 | 74.70 Mn |
| Sep 30, 2022 | 49.70 Mn |
| Jun 30, 2022 | 42.10 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 54.40 Mn |
| Sep 30, 2021 | 4.67 Mn |